Compare Biogen Inc (BIIB) vs EOG Resources Inc (EOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs EOG Resources Inc — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while EOG Resources Inc trades at $138.3 (market cap $73.51B). The key difference: EOG Resources Inc is far larger — about 2.6× Biogen Inc's market cap, and EOG Resources Inc pays a 2.96% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | EOG | |
|---|---|---|
Market Cap | $28.34B | $73.51B |
Sector | Health | Energy |
52-Week High | $216.63 | $149.89 |
52-Week Low | $122.68 | $101.78 |
Enterprise Value | $30.62B | $77.97B |
Dividend Yield | — | 2.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
EOG Resources trades at $139.61, up 4.11% with a bullish technical outlook. The stock shows strong profitability with a net margin of 23.39% and ROE of 18.19%, supported by consistent earnings beats. Valuation ratios like P/E of 13.73 and EV/EBITDA of 6.6 appear attractive relative to historical levels. Recent news highlights operational excellence and dividend stability, with Q2 2026 earnings anticipated on August 5, 2026.
The outlook remains positive with a consensus price target of $156.40, implying 12% upside. Risks include oil price volatility and elevated capital expenditures, but EOG's low-cost production and solid balance sheet provide resilience. Analyst sentiment is strongly bullish with no sell ratings, reinforcing the investment case for growth and income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →
